Company news

Trevi Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

December 15, 2024

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

December 11, 2024

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

December 2, 2024

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

November 20, 2024

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

November 5, 2024

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

October 29, 2024

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

October 20, 2024

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

October 14, 2024

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

October 2, 2024

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

September 29, 2024

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

September 25, 2024

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

September 3, 2024

Trevi Therapeutics to Participate in September Investor and Medical Conferences

August 27, 2024

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance

August 7, 2024

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024

July 31, 2024

Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events

July 1, 2024

Trevi Therapeutics to Participate in Upcoming Conferences

May 8, 2024

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024

Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024

April 30, 2024

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

April 8, 2024

Trevi Therapeutics to Participate in Upcoming April Events

April 3, 2024

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

April 1, 2024

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

March 19, 2024

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024

March 12, 2024

Trevi Therapeutics to Participate in Upcoming March Events

February 27, 2024

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024

Trevi Therapeutics Provides Business Updates

January 3, 2024

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

December 4, 2023

Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023

Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough

November 1, 2023

Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023

October 31, 2023

Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis

October 12, 2023

Trevi Therapeutics to Participate in Upcoming September Events

September 5, 2023

Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update

August 9, 2023

Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023

August 2, 2023

Trevi Therapeutics to Participate in Upcoming August Events

July 31, 2023

Trevi Therapeutics to Participate in Upcoming July Investor Events

July 5, 2023

Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence

May 21, 2023

Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023

Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023

May 8, 2023

Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023

May 3, 2023

Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference

May 1, 2023

Trevi Therapeutics to Participate in Upcoming May Investor Events

April 26, 2023

Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

March 15, 2023

Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023

March 8, 2023

Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

March 7, 2023

Trevi Therapeutics to Participate in Upcoming March Conferences

March 5, 2023

Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023

February 15, 2023

Trevi Therapeutics to Present and Participate in Upcoming February Conferences

February 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.